4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541) operates in the Biotechnology industry and is headquartered in Shanghai, China with about 201 employees. Its market capitalization is roughly CNY 2 billion. In the fiscal year ended 2025-12-31, 1541 reported CNY 154M in revenue and (CNY 219M) in net income.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc., a biotechnology company, engages in the research and development of immuno-oncology therapies in China and the United States.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | CNY 154M | CNY 74M | CNY 0M | CNY 0M | — |
| Gross Profit | CNY 153M | CNY 74M | — | — | — |
| Operating Income (EBIT) | (CNY 213M) | (CNY 308M) | (CNY 391M) | (CNY 382M) | — |
| Net Income | (CNY 219M) | (CNY 316M) | (CNY 380M) | (CNY 403M) | — |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | CNY 1.1B | CNY 922M | CNY 875M | CNY 840M | — |
| Total Liabilities | CNY 308M | CNY 244M | CNY 126M | CNY 61M | — |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 1541 viewer.
About TickerBase · Data methodology & sources · Privacy · Terms